New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.

Florian RosarSebastian DewesMartin RiesAndrea SchaeferFadi KhreishStephan MausHendrik BohnenbergerJohannes LinxweilerMark BartholomäCarsten OhlmannSamer Ezziddin

Published in: European journal of nuclear medicine and molecular imaging (2020)

Our results suggest that enzalutamide could be considered as a PSMA radioligand treatment enhancing primer medication, which may increase PSMA expression by a dimension of 50% in mCRPC. The effect was shown even in patients having previously failed enzalutamide treatment for arrest of progression in the mCRPC setting. Our observation deserves evaluation in a prospective setting.

Keyphrases

prostate cancer
pet ct
poor prognosis
end stage renal disease
ejection fraction
pet imaging
newly diagnosed
chronic kidney disease
peritoneal dialysis
signaling pathway
computed tomography
patient reported outcomes
emergency department
replacement therapy
positron emission tomography